Advertisement · 728 × 90

Posts by Diamyd Medical

📹 9.00 presenterar Diamyd Medical vid G&W Småbolagsfrukost

ir.financialhearings.com/gw-smabolags...

2 years ago 0 0 0 0
Preview
Unearthing Diabetes Discoveries #1 | Ulf Hannelius, Diamyd Medical Welcome to Unearthing Diabetes Discoveries, your inside look at cutting-edge diabetes research. In this episode, I chat with Ulf Hannelius, CEO of Diamyd Medical, about their groundbreaking investigat...

🎧 PODCAST - #Diabetes Daily Grind in a conversation on Diamyd Medicals pioneering investigational immunotherapy, currently undergoing phase-III clinical trials.

diabetesdailygrind.com/unearthing-d...

2 years ago 0 0 0 0
Official website for ASSET - AI for Sustainable Prevention of Autoimmunity in the Society ASSET is an innovation milieu with the aim of developing and evaluating AI algorithms to assess the individual risk of developing type 1 diabetes.

🧬🔬Find out more about ASSET (AI for Sustainable Prevention of Autoimmunity in the Society), a milieu contributing to the development of strategies for personalised prediction and prevention of autoimmune diseases. www.asset.healthcare

2 years ago 0 0 0 0

How can AI improve T1D screening?

✍️Check article published in Diabetologia, the authoritative journal dedicated to the study of #diabetes.
link.springer.com/content/pdf/...

2 years ago 0 0 1 0
Preview
Trading Direkt Healthcare 2024-02-19 | Kvartalsrapporter från Bioarctic och Camurus 00:00 Intro00:48 Uppdatering om Bioarctic efter bokslutet 202305:24 Synen på specialistläkemedelsbolaget Camurus bokslut 202310:09 Nedskrivningen av goodwill...

Trading Direkt Healthcare: "Forskningsbolaget Diamyd Medical har beviljats snabbehandlingsstatus av den amerikanska läkemedelsmyndigheten FDA för sin vaccinkandidat Diamyd inom området för typ 1-diabetes."

$DMYDB

2 years ago 0 0 0 0
Preview
Diamyd Medical | Live 16:00 (CET) Diamyd comment on FDA Fast Track designation granted President & CEO, Ph.D Ulf Hannelius and board member MD & Ph.D Karin Rosén participates. Viewers can ask questions in the live chat.

🎥 Live broadcast 19/2 at 16:00 CET with @diamyd.com CEO & board member, discussing the @fda.gov granted Fast Track designation & its implications for the development of the antigen-specific immunotherapy for type 1 #diabetes.
Chat open for questions. Welcome! đź’™ youtube.com/live/GzWKvOM...

2 years ago 0 0 0 0
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

www.diamyd.com/docs/pressClips.aspx?ClipID=4751158

2 years ago 1 0 0 0
Advertisement

Diamyd® is currently being evaluated in the first-ever #precisionmedicine Phase III trial www.DIAGNODE-3.com in individuals recently diagnosed with Type 1 #Diabetes carrying the HLA DR3-DQ2 genotype. #t1d

2 years ago 0 0 0 0
Diamyd® is currently being evaluated in the first-ever precision medicine Phase III trial www.DIAGNODE-3.com in individuals recently diagnosed with Type 1 Diabetes carrying the HLA DR3-DQ2 genotype.

Diamyd® is currently being evaluated in the first-ever precision medicine Phase III trial www.DIAGNODE-3.com in individuals recently diagnosed with Type 1 Diabetes carrying the HLA DR3-DQ2 genotype.

We are very pleased with the @fda.gov decision to grant Fast Track designation for #Diamyd and the potential this provides to accelerate Diamyd’s path to entering the US market", says Ulf Hannelius, CEO of Diamyd Medical. 💙

2 years ago 1 0 2 0